Dextran

Overview

Dextran is a polysaccharide that differs from others in that its glucose units are joined together 1:6 glucoside links. The main chain of glucose has short branches at frequent intervals which are probably joined by 1:3 and 1:4 glucoside links. The chains can be composed of about 200,000 glucose units. Many bacteria, like Leuconostoc, can synthesize dextran from sucrose, and this activity is used commercially to obtain dextran. Dextran 40 is a sterile, nonpyrogenic preparation of low molecular weight dextran (average mol. wt. 40,000) in 5% Dextrose Injection or 0.9% Sodium Chloride Injection. It is administered by intravenous infusion. Dextran 75 is a complex branched glucan with an average molecular weight 75000 Daltons. It is produced from certain bacteria that with α-1,6 glycosidic linkages between glucose molecules and α-1,3 linkages between branches. When labelled with technetium Tc99m, dextran 75 is intravenously administered as an imaging agent to detect and diagnose conditions in the vascular compartment such as pericardial effusion or ventricular aneurysm.

Indication

Dextran is used as the restoration of blood mass during surgical interventions if there is hypovolemia due to trauma or dehydration. It is as well used after the presence of hemorrhage in cases of blood loss to a level inferior to 15% of the blood mass, if compatibility test cannot be completed or when blood lots need to be tested for pathogen detection. Dextran is also used for the prevention of profound postoperative venous thrombosis. Dextran as well presents ophthalmic applications as solutions or ointments for the temporary relief of xerophthalmia or minor ocular irritations.

Associated Conditions

Blood Circulation Disorder
Capillary disorder
Dry Eyes
Ocular Irritation
Pulmonary Embolism
Pulmonary Embolism caused by procedures associated with a high incidence of thromboembolic complications
Shock
Thrombosis
Venous Thrombosis (Disorder)
Venous Thrombosis caused by procedures associated with a high incidence of thromboembolic complications

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study	2022/09/07	NCT05530356	N/A	ENROLLING_BY_INVITATION	University of Colorado, Denver
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis	2022/04/06	NCT05314621	Phase 4	Completed	Andover Research Eye Institute
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis	2022/03/04	NCT05265910	Phase 4	Completed	Andover Research Eye Institute
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)	2021/08/17	NCT05008276	N/A	Recruiting	Petter Bjornstad
Sjögren's Syndrome Is Associated With Meibomian Gland Dysfunction	2018/02/15	NCT03434106	Not Applicable	UNKNOWN	LanZhou University
Effects of Two Tear Substitutes in Patients With Dry Eye Syndrome	2017/07/07	NCT03211351	Not Applicable	Completed	Huaxia Eye Hospital Group
Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury	2017/03/03	NCT03070353	Phase 2	Completed	Ramathibodi Hospital
Is Sjögren's Syndrome Associated With Meibomian Gland Dysfunction ?	2017/02/23	NCT03060005	Not Applicable	UNKNOWN	Tung Wah Hospital
Comparison of the Clinical Effects of Two Tear Substitutes in Patients With Dry Eye Syndrome	2016/12/14	NCT02992392	Not Applicable	UNKNOWN	Sun Yat-sen University
Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit	2016/08/11	NCT02863809	Phase 1	Completed	Joseph B. Ciolino, MD

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
LMD in Sodium Chloride	Hospira, Inc.	0409-7419	INTRAVENOUS	10 g in 100 mL	2/15/2023
LMD in Dextrose	Hospira, Inc.	0409-7418	INTRAVENOUS	10 g in 100 mL	2/15/2023
Colirio Ocusan	DLC Laboratories, Inc.	24286-1575	OPHTHALMIC	1 mg in 1 mL	4/18/2025
GoodSense Eye Drops Advanced Relief Moisturizer	Preferred PHarmaceuticals Inc.	68788-8635	OPHTHALMIC	0.1 g in 100 mL	5/7/2025

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
10% Dextran 40 in 0.9% Sodium chloride 500mL injection bag FKB5043G	19427	Baxter Healthcare Pty Ltd	Medicine	A	9/30/1991
6% Dextran 70 in 5% Glucose 500mL injection FKB5063G	19428	Baxter Healthcare Pty Ltd	Medicine	A	9/30/1991
10% Dextran 40 in 5% Glucose 500mL injection FKB5053G	19426	Baxter Healthcare Pty Ltd	Medicine	A	9/30/1991
6% Dextran 70 in 0.9% Sodium chloride 500mL injection FKB5013G	19429	Baxter Healthcare Pty Ltd	Medicine	A	9/30/1991

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
LMD 10% IN DEXTROSE 5%	Pfizer Canada Ulc	00224235	Solution - Intravenous	10 %	12/31/1968
GENTRAN 40 10% SODIUM CHLORIDE 0.9% INJ	baxter corporation	00454923	Liquid - Intravenous	10 G / 100 ML	12/31/1979
6% DEXTRAN 70 IN 0.9% SODIUM CHLORIDE INJECTION	b. braun medical inc	01924192	Solution - Intravenous	6 %	9/10/1996
LMD 10% IN 0.9% SODIUM CHLORIDE	Pfizer Canada Ulc	00224227	Solution - Intravenous	10 %	12/31/1968
VISINE FOR RED EYE WORKPLACE	johnson & johnson inc	02436086	Drops - Ophthalmic	0.1 % / W/V	6/3/2016
VISINE FOR RED EYE COOL	johnson & johnson inc	02328399	Drops - Ophthalmic	0.1 % / W/V	4/15/2010
TEARS NATURALE	Alcon Canada Inc	00390291	Solution - Ophthalmic	0.1 %	12/31/1977
RHEOMACRODEX 10% IN NORMAL SALINE	pharmacia (canada) inc.	00213926	Liquid - Intravenous	10 G / 100 ML	12/31/1962
AQUASITE DPS	CIBA Vision Canada Inc	02029901	Drops - Ophthalmic	.1 %	12/31/1993
ADVANCED RELIEF EYE DROPS	juno otc inc	02344319	Solution - Ophthalmic	0.1 % / W/V	8/30/2010

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
DACROLUX 3MG/ML +1MG/ML COLIRIO EN SOLUCIÓN	Reva Health Europe S.L.	58742	COLIRIO EN SOLUCIÓN	Sin Receta	Not Commercialized
RHEOMACRODEX 10% SALINO	Fresenius Kabi España, S.A.U.	39627	SOLUCIÓN PARA PERFUSIÓN	Uso Hospitalario	Not Commercialized

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access